HR+ Disease

HR+ Disease

Early morning view of a waterfront with a promotional banner for OncUpdates, featuring Dr. Hope Rugo and two other doctors discussing metastatic HR+ breast cancer highlights for SABCS 2025.

HR+ Disease

02/06/2026

HR+ Metastatic Breast Cancer Updates from SABCS 2025

Hope Rugo, MD, FASCORahul Gosain, MD, MBARohit Gosain, MD

Inovative breast cancer research and treatment insights from OncUpdates, featuring experts Tyler Kristoff, MD, and Sarah Premji, MD, focusing on the role of Inavolisib as a first-line therapy and emerging oral SERDs.

HR+ Disease

01/13/2026

SABCS 2025 Updates on Inavolisib and Giredestrant in Breast Cancer

Tyler Kristoff, MDSarah Premji, MD

1. In-depth analysis of HR+ and early breast cancer studies from SABCS 2025 featuring experts Dr. Rohit Gosain, Dr. Rahul Gosain, and Dr. Laura Huppert.

HR+ Disease

01/12/2026

Key HR+, Early Breast Cancer Abstracts From SABCS 2025

Laura Huppert, MDRahul Gosain, MD, MBARohit Gosain, MD

1. Female healthcare professionals discussing breast cancer prevention and patient advocacy for cancer care education and empowerment.

HR+ Disease

01/04/2026

Patient Advocacy Brings Breast Cancer Vaccine to Phase 1 Trial

Judy FitzgeraldKarissa Britten, MD

Enhanced image of two medical professionals discussing CDK4/6 inhibitors for cancer treatment at OncUpdates, with a cityscape background highlighting expertise in oncology research and therapy options.

HR+ Disease

01/02/2026

NATALEE 5-Year IDFS Data at SABCS 2025

Matthew Kurian, MDJasmin Hundal, MD

1. Interpreting MONALEESA, NATALEE, and monarchE in clinical oncology practice, featuring healthcare professionals discussing advanced breast cancer treatments.

HR+ Disease

12/29/2025

SABCS 2025: Expert Perspective on CDK4/6 Inhibitor Use in Metastatic Hormone Receptor-Positive Breast Cancer

Matthew Kurian, MDElia Segui Solis, MD

Innovative hormone receptor-positive breast cancer treatment paradigms discussed by Dr. Jasmin Hundal, expert from Cleveland Clinic, highlighting advancements and research updates in oncology.

HR+ Disease

12/27/2025

Shifting Treatment Paradigms in Hormone Receptor–Positive Breast Cancer

Jasmin Hundal, MD

Adjuvant CDK4/6 inhibition in early breast cancer discussed by renowned experts Matthew Kurian and Komal Jhaveri at OncUpdates.

HR+ Disease

12/21/2025

NATALEE and Other Updates for HR+ Early Breast Cancer at SABCS 2025

Komal Jhaveri, MD, FACPMatthew Kurian, MD

1. Advances in early-stage breast cancer treatment focusing on CDK4/6 inhibitors for adjuvant therapy.

HR+ Disease

12/19/2025

Key Insights From the NATALEE Trial

Karissa Britten, MDMatthew Kurian, MD

1. AlT text: Expert discussion on managing breast cancer relapse with adjuvant CDK4/6 inhibitor therapy in ER-positive cases, featuring Dr. Sarah Premji and Dr. Kevin Kalinsky.

HR+ Disease

12/18/2025

SABCS 2025: Evolving Role of CDK4/6 Inhibitors and SERDs in ER-Positive Breast Cancer

Kevin Kalinsky, MD, MS, FASCOSarah Premji, MD